Avastin effective in AMD
Bethesda – VEGF-A blockers Lucentis and Avastin have shown similar efficacy in patients with age-related macular degeneration (AMD), according to one-year results from the CATT study performed on more than 1,000 AMD patients. This is bad news for Novartis AG, which markets Lucentis in Europe. While the antibody fragment is 40 times more expensive than the full antibody, Roche’s Avastin has been used extensively off-label by ophthalmologists. Roche remains reluctant to file an MAA for Avastin in AMD, however, saying there were more side effects observed with Avastin in the CATT study. However, CATT investigators said it was still too early to comment on safety issues, because any statement wouldn’t be backed up by statistically significant data.